Impact of CYP2C19 genotype on escitalopram exposure and establishment of a dose algorithm for genotype-based individualization of escitalopram therapy

被引：0
|
作者：
Jukic, M. [1 ]
Molden, E. [2 ]
Ingelman-Sundberg, M. [1 ]
机构：
[1] Karolinska Inst, Dept Physiol & Pharmacol, Stockholm, Sweden
[2] Univ Oslo, Sch Pharm, Dept Pharmaceut Biosci, Oslo, Norway
来源：
EUROPEAN NEUROPSYCHOPHARMACOLOGY | 2017年 / 27卷
关键词：
D O I：
10.1016/S0924-977X(17)31537-7
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P.2.f.017
引用
收藏
页码：S856 / S856
页数：1
相关论文
共 50 条
  • [41] A POPULATION PHARMACOKINETIC ANALYSIS OF ESCITALOPRAM AND THE EFFECT OF CYP2C19 ON CLEARANCE IN CHILDREN AND ADOLESCENTS
    Poweleit, E.
    Mizuno, T.
    Taylor, Z.
    Vaughn, S.
    Desta, Z.
    Strawn, J.
    Ramsey, L.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2023, 113 : S25 - S25
  • [42] PHARMACOGENETIC INFLUENCE OF CYP2C19 VARIATION ON ESCITALOPRAM PHARMACOKINETICS IN CHILDREN AND ADOLESCENTS.
    Poweleit, E.
    Vaughn, S.
    Desta, Z.
    Strawn, J.
    Ramsey, L.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2022, 111 : S41 - S41
  • [43] CYP2C19 Metabolizer Status Predicts Sertraline and Escitalopram Pharmacokinetics in Children and Adolescents
    Poweleit, Ethan
    Vaughn, Samuel
    Desta, Zeruesenay
    Ramsey, Laura
    Strawn, Jeffrey
    NEUROPSYCHOPHARMACOLOGY, 2021, 46 (SUPPL 1) : 154 - 154
  • [44] Impact of CYP2C19 genotype on voriconazole exposure and effect of voriconazole on the activity of CYP3A in patients with haematological malignancies
    Huang, Fengru
    Zhou, Chen
    Zhang, Xiao-Yan
    Shen, Miss Ye
    Zhang, Hongwen
    Wang, Yongqing
    Sun, Luning
    XENOBIOTICA, 2021, 51 (10) : 1199 - 1206
  • [45] Does CYP2C19 genotype affect clinical outcome?
    ten Berg, Jurrien M.
    Deneer, Vera H.
    NATURE REVIEWS CARDIOLOGY, 2012, 9 (04) : 192 - 194
  • [46] Does CYP2C19 genotype affect clinical outcome?
    Jurriën M. ten Berg
    Vera H. Deneer
    Nature Reviews Cardiology, 2012, 9 : 192 - 194
  • [47] CYP2C19 GENOTYPE SIGNIFICANTLY AFFECTS THE PHARMACOKINETICS OF TOLPERISONE
    Byeon, J.
    Lee, H.
    Choi, C.
    Lee, Y.
    Jang, C.
    Bae, J.
    Lee, S.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2013, 93 : S23 - S24
  • [48] Kinetics of omeprazole and escitalopram in relation to the CYP2C19*17 allele in healthy subjects
    Staffan Ohlsson Rosenborg
    Jessica Mwinyi
    Maria Andersson
    R. Michael Baldwin
    Rasmus Steen Pedersen
    Sarah C. Sim
    Leif Bertilsson
    Magnus Ingelman-Sundberg
    Erik Eliasson
    European Journal of Clinical Pharmacology, 2008, 64 : 1175 - 1179
  • [49] Effects of CYP2C19 Genotype on Outcomes of Clopidogrel Treatment
    Pare, Guillaume
    Mehta, Shamir R.
    Yusuf, Salim
    Anand, Sonia S.
    Connolly, Stuart J.
    Hirsh, Jack
    Simonsen, Katy
    Bhatt, Deepak L.
    Fox, Keith A. A.
    Eikelboom, John W.
    NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (18): : 1704 - 1714
  • [50] CYP2C19 Genotype and Outcomes of Clopidogrel Treatment REPLY
    Pare, Guillaume
    Mehta, Shamir R.
    Eikelboom, John W.
    NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (05): : 482 - 482
12345